IIT Delhi show cause notice to in-house incubated startup, Sanfe, for allegedly falsely stating FDA approval for one of

1. IIT Delhi show cause notice to in-house incubated startup, Sanfe, for allegedly falsely stating FDA approval for one of their products On 8th March, on the occasion of International Women’s Day, IIT Delhi incubated startup, Sanfe, launched Sanfe Period Pain Relief Roll On for women’s menstrual comfort. The product was introduced in the market to empower women and ensure their productivity even during periods which happens to obstruct their daily life rituals due to menstrual cramps. The product had received a significant response from women and also the media. However, during the launch, one information was miscommunicated by the Co- Founders, Archit Agarwal and Harry Sehrawat regarding the product. They had said in the event that Sanfe Period Pain Relief Roll On was FDA approved but failed to mention Ministry of Ayush which regulates ayurvedic and natural products in India. It was a genuine misunderstanding on both the parts since Archit and Harry were not informed that FDA regulations take place only in USA and Ministry of Ayushi in India. As soon as they realised the mistake on their part, they issued a corrigendum in a major leading newspaper, The Hindu, to inform everyone about the mistake that happened. IIT Delhi show caused a notice to the team to inquire if the claim was a deliberate attempt from their students Archit Agarwal and Harry Sehrawat, and the review committee is yet to bring up the final decision against the duo. Sanfe team ensured that the packaging and every content that informed about the approval was rectified and a mail had also been shot to its customers who had purchased the product to inform them regarding the miscommunication.